9 results match your criteria: "Centre d'Investigations Cliniques-1433 and INSERM U1116[Affiliation]"

Machine Learning-Based Phenogrouping in MVP Identifies Profiles Associated With Myocardial Fibrosis and Cardiovascular Events.

JACC Cardiovasc Imaging

October 2023

CHU Nantes, Université de Nantes, l'Institut du Thorax, Centre Investigation Clinique 1413, Nantes, France; Université de Nantes, CHU de Nantes, CNRS, INSERM, l'Institut du Thorax, Nantes, France.

Background: Structural changes and myocardial fibrosis quantification by cardiac imaging have become increasingly important to predict cardiovascular events in patients with mitral valve prolapse (MVP). In this setting, it is likely that an unsupervised approach using machine learning may improve their risk assessment.

Objectives: This study used machine learning to improve the risk assessment of patients with MVP by identifying echocardiographic phenotypes and their respective association with myocardial fibrosis and prognosis.

View Article and Find Full Text PDF

Background: Patient knowledge is crucial for managing and/or monitoring patients with heart failure (HF). However, "real-life" evidence of knowledge level and awareness in HF is yet to be explored. We assessed unselected HF patients' knowledge and awareness in a pharmacy setting.

View Article and Find Full Text PDF
Article Synopsis
  • About half of patients with heart failure (HF) have HF with preserved ejection fraction (HFpEF), which poses challenges in diagnosis and treatment due to its complex underlying mechanisms.
  • Advanced diagnostic techniques may be needed to distinguish HFpEF from other causes of breathing difficulties, as traditional reliance on left ventricular ejection fraction (LVEF) cut-points may not adequately capture the nuances of this condition.
  • Effective management of HFpEF includes lifestyle modifications, treatment of comorbidities, and the use of specific medications like sodium-glucose cotransporter 2 inhibitors, while a phenotypic classification approach may offer more tailored treatment strategies compared to the standard LVEF categories.
View Article and Find Full Text PDF
Article Synopsis
  • Heart failure RCTs have low representation of BIPOC, with only 37.9% reporting race and ethnicity data and 18.7% of participants being BIPOC.
  • There was a significant increase in both the reporting of race and ethnicity data and BIPOC enrollment from 2000 to 2020.
  • Trials led by women were more likely to report race and ethnicity data and had higher enrollment of BIPOC participants.
View Article and Find Full Text PDF
Article Synopsis
  • * An analysis revealed that various health markers, like changes in blood components (haematocrit and haemoglobin) and kidney function (urine albumin-to-creatinine ratio), significantly impacted the effectiveness of empagliflozin in reducing heart-related risks.
  • * Specifically, the study concluded that changes in haematocrit and haemoglobin were the key factors in reducing heart failure risks among these patients, while other markers played a smaller role.
View Article and Find Full Text PDF

Background: Atrial fibrillation (AF) leads to the development of cardiac remodeling/diastolic dysfunction and vice versa. We intended to determine whether cardiac remodeling/diastolic dysfunction is present at early stages of AF.

Methods: We studied 175 patients with paroxysmal AF, compared with 175 matched control subjects, who had available echocardiography data to investigate the association between echocardiographic variables and AF from the STANISLAS cohort.

View Article and Find Full Text PDF

Aims: The geographic representation of investigators and participants in heart failure (HF) randomized controlled trials (RCTs) may not reflect the global distribution of disease. We assessed the geographic diversity of RCT leaders and explored associations with geographic representation of enrolled participants among impactful HF RCTs.

Methods And Results: We searched MEDLINE, EMBASE, and CINAHL for HF RCTs published in journals with impact factor ≥ 10 between January 2000 and June 2020.

View Article and Find Full Text PDF

Cardiorenal Syndrome Revisited.

Circulation

August 2018

Universite de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, France (F.Z., P.R.).

Cardiorenal syndromes have been categorized into 5 clinical subtypes based on which organ is perceived to be the primary precipitant of the vicious and interrelated cycle of declining function in both organs. This clinical classification has broadened interest in cardiorenal interactions, but it is merely descriptive, does not rely on or inform predominant pathophysiology, and has produced little change in either practice or the research agenda. In contrast, recent scientific work identifies common pathophysiological pathways for several categories of cardiorenal syndromes, suggesting a unifying pathogenesis.

View Article and Find Full Text PDF

Patients with chronic kidney failure--defined as a glomerular filtration rate persistently below 15 mL/min per 1·73 m(2)--have an unacceptably high mortality rate. In developing countries, mortality results primarily from an absence of access to renal replacement therapy. Additionally, cardiovascular and non-cardiovascular mortality are several times higher in patients on dialysis or post-renal transplantation than in the general population.

View Article and Find Full Text PDF